ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC

Authors:

Abstract
No abstract available
Funding Information
  • AstraZeneca
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Bristol-Myers Squibb
  • EMD Serono
  • Spectrum Pharmaceuticals
  • Takeda Pharmaceuticals U.S.A.
  • Eli Lilly and Company
  • Merck KGaA

This publication has 9 references indexed in Scilit: